The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis

Abstract To assess the influence of lipid-lowering therapy on coronary plaque volume, and to identify the LDL and HDL targets for plaque regression to provide a comprehensive overview. The databases searched (from inception to 15 July 2020) to identify prospective studies investigating the impact of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yingrui Li, Songbai Deng, Bin Liu, Yulin Yan, Jianlin Du, Yu Li, Xiaodong Jing, Yajie Liu, Jing Wang, Jun Du, Qiang She
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f35eb3703589472c97527e147bc0ae56
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f35eb3703589472c97527e147bc0ae56
record_format	dspace
spelling	oai:doaj.org-article:f35eb3703589472c97527e147bc0ae562021-12-02T15:51:12ZThe effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis10.1038/s41598-021-87528-w2045-2322https://doaj.org/article/f35eb3703589472c97527e147bc0ae562021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87528-whttps://doaj.org/toc/2045-2322Abstract To assess the influence of lipid-lowering therapy on coronary plaque volume, and to identify the LDL and HDL targets for plaque regression to provide a comprehensive overview. The databases searched (from inception to 15 July 2020) to identify prospective studies investigating the impact of lipid-lowering therapy on coronary plaque volume and including quantitative measurement of plaque volume by intravascular ultrasound after treatment. Thirty-one studies that included 4997 patients were selected in the final analysis. Patients had significantly lower TAV (SMD: 0.123 mm3; 95% CI 0.059, 0.187; P = 0.000) and PAV (SMD: 0.123%; 95% CI 0.035, 0.212; P = 0.006) at follow-up. According to the subgroup analyses, TAV was significantly reduced in the LDL < 80 mg/dL and HDL > 45 mg/dL group (SMD: 0.163 mm3; 95% CI 0.092, 0.234; P = 0.000), and PAV was significantly reduced in the LDL < 90 mg/dL and HDL > 45 mg/dL group (SMD: 0.186%; 95% CI 0.081, 0.291; P = 0.001).Thirty-one studies that included 4997 patients were selected in the final analysis. Patients had significantly lower TAV (SMD: 0.123 mm3; 95% CI 0.059, 0.187; P = 0.000) and PAV (SMD: 0.123%; 95% CI 0.035, 0.212; P = 0.006) at follow-up. According to the subgroup analyses, TAV was significantly reduced in the LDL < 80 mg/dL and HDL > 45 mg/dL group (SMD: 0.163 mm3; 95% CI 0.092, 0.234; P = 0.000), and PAV was significantly reduced in the LDL < 90 mg/dL and HDL > 45 mg/dL group (SMD: 0.186%; 95% CI 0.081, 0.291; P = 0.001). Our meta-analysis suggests that not only should LDL be reduced to a target level of < 80 mg/dL, but HDL should be increased to a target level of > 45 mg/dL to regress coronary plaques. Trial Registration PROSPERO identifier: CRD42019146170.Yingrui LiSongbai DengBin LiuYulin YanJianlin DuYu LiXiaodong JingYajie LiuJing WangJun DuQiang SheNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yingrui Li Songbai Deng Bin Liu Yulin Yan Jianlin Du Yu Li Xiaodong Jing Yajie Liu Jing Wang Jun Du Qiang She The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis
description	Abstract To assess the influence of lipid-lowering therapy on coronary plaque volume, and to identify the LDL and HDL targets for plaque regression to provide a comprehensive overview. The databases searched (from inception to 15 July 2020) to identify prospective studies investigating the impact of lipid-lowering therapy on coronary plaque volume and including quantitative measurement of plaque volume by intravascular ultrasound after treatment. Thirty-one studies that included 4997 patients were selected in the final analysis. Patients had significantly lower TAV (SMD: 0.123 mm3; 95% CI 0.059, 0.187; P = 0.000) and PAV (SMD: 0.123%; 95% CI 0.035, 0.212; P = 0.006) at follow-up. According to the subgroup analyses, TAV was significantly reduced in the LDL < 80 mg/dL and HDL > 45 mg/dL group (SMD: 0.163 mm3; 95% CI 0.092, 0.234; P = 0.000), and PAV was significantly reduced in the LDL < 90 mg/dL and HDL > 45 mg/dL group (SMD: 0.186%; 95% CI 0.081, 0.291; P = 0.001).Thirty-one studies that included 4997 patients were selected in the final analysis. Patients had significantly lower TAV (SMD: 0.123 mm3; 95% CI 0.059, 0.187; P = 0.000) and PAV (SMD: 0.123%; 95% CI 0.035, 0.212; P = 0.006) at follow-up. According to the subgroup analyses, TAV was significantly reduced in the LDL < 80 mg/dL and HDL > 45 mg/dL group (SMD: 0.163 mm3; 95% CI 0.092, 0.234; P = 0.000), and PAV was significantly reduced in the LDL < 90 mg/dL and HDL > 45 mg/dL group (SMD: 0.186%; 95% CI 0.081, 0.291; P = 0.001). Our meta-analysis suggests that not only should LDL be reduced to a target level of < 80 mg/dL, but HDL should be increased to a target level of > 45 mg/dL to regress coronary plaques. Trial Registration PROSPERO identifier: CRD42019146170.
format	article
author	Yingrui Li Songbai Deng Bin Liu Yulin Yan Jianlin Du Yu Li Xiaodong Jing Yajie Liu Jing Wang Jun Du Qiang She
author_facet	Yingrui Li Songbai Deng Bin Liu Yulin Yan Jianlin Du Yu Li Xiaodong Jing Yajie Liu Jing Wang Jun Du Qiang She
author_sort	Yingrui Li
title	The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis
title_short	The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis
title_full	The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis
title_fullStr	The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis
title_full_unstemmed	The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis
title_sort	effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f35eb3703589472c97527e147bc0ae56
work_keys_str_mv	AT yingruili theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT songbaideng theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT binliu theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT yulinyan theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT jianlindu theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT yuli theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT xiaodongjing theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT yajieliu theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT jingwang theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT jundu theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT qiangshe theeffectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT yingruili effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT songbaideng effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT binliu effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT yulinyan effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT jianlindu effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT yuli effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT xiaodongjing effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT yajieliu effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT jingwang effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT jundu effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis AT qiangshe effectsoflipidloweringtherapyoncoronaryplaqueregressionasystematicreviewandmetaanalysis
_version_	1718385667732406272

The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis

Ejemplares similares